Short Wave Short Wave

Does the science of peptides live up to the hype?

Jul 22, 2026 · 12m

Summary

NPR’s Shortwave examines the surge in synthetic peptide use among fitness influencers and the associated safety concerns. Health reporter Sarah Bowden discusses the lack of human clinical data, risks like cancer promotion, and the prevalence of unregulated gray markets. The episode explores potential FDA regulatory changes, weighing harm reduction strategies against strict safety protocols to mitigate public health risks.

Topics discussed

Intro: Sponsor message and show welcome What are peptides? The rise in popularity and FDA scrutiny Sponsors: Schwab, NetSuite, and BetterHelp Scientific evidence: Lack of human trials and cancer risks The gray market: Buying unregulated research-grade peptides Harm reduction: Arguments for regulated compounding pharmacies FDA decision: Conflict of interest and legal perspectives Future outlook: Prescription access and insurance coverage Outro: Credits and final sponsor messages

More from Short Wave

This gas station drug acts like opioids. It’s getting harder to buy
Nov 20, 2026
How a viral video gave a huge boost to new gene therapy
Nov 18, 2026
How bird poop and manta rays sustain a pristine coral reef
Nov 17, 2026
Are your body clocks off? Meet ‘circadian depression’
Nov 16, 2026
AI could help hospitals diagnose PTSD in real time
Nov 13, 2026
Listen ad-free on Castria